[1] Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer [J]. Curr Opin Chem Biol, 2002, 6: 493-500.
[2] Bernhard EJ, Mitchell JB, Deen D, et al. Re-evaluating gadolinium( III) texaphyrin as a radiosensitizing agent [J]. Cancer Res, 2000, 60: 86-91.
[3] Bradbury CM, Markovina S, Wei SJ, et al. Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-kappaB activation in HeLa cells occur via a mechanism involving p38 MAP kinase [J]. Cancer Res, 2001, 61: 7689-7696.
[4] Busby EC, Leistritz DF, Abraham RT, et al. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1 [J]. Cancer Res, 2000, 60: 2108-2112.
[5] Chun YJ, Park IC, Park MJ, et al. Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3) [J]. FEBS Lett, 2002, 519: 195-200.
[6] Cividalli A, Ceciarelli F, Livdi E, et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma : influence of treatment schedule [J]. Int J Radiat Oncol Biol Phys, 2002, 52: 1092-1098.
[7] Colletier PJ, Ashoori F, Cowen D, et al. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation [J]. Int J Radiat Oncol Biol Phys, 2000, 48: 1507-1512.
[8] Cowen D, Salem N, Ashoori F, et al. Prostate cancer radio-sensitization in vivo with adenovirus-mediated p53 gene therapy [J]. Clin Cancer Res, 2000, 6: 4402-4408.
[9] Curran WJ Jr, Choy H. Optimizing chemoradiation in locally advanced non-small-cell lung cancer [J]. Oncology (Huntingt), 2001, 15: 43-45.
[10] de Lange SM, van Groeningen CJ, Meijer OWM, et al. Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer [J]. Eur J Cancer, 2002, 38: 1212-1217.
[11] Edgren M, Lennernas B. Estramustine, a radiosensitising agent [J]. Anticancer Res, 2000, 20: 2677-2680.
[12] Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer : a phase I trial and intracellular drug incorporation study [J]. J Clin Oncol, 2001, 19: 792-799.
[13] Epelbaum R, Rosenblatt E, Nasrallah S, et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer [J]. J Surg Oncol, 2002, 81: 138-43.
[14] Fan Z, Chakravarty P, Alfieri A, et al. Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation [J]. Cancer Gene Ther, 2000, 7: 1307-1314.
[15] Feng HX, Lu RB, Hu LY, et al. Clinical study and nursing of the radiosensitizing effect of CMNa on nasopharyngeal cancer in radiotherapy [J]. Modern Nursing, 2002, 8: 86-87.
[16] Ferrandina G, Filippini P, Ferlini C, et al. Growth inhibitory effects and radiosensitization induced by fatty aromatic acids on human cervical cancer cells [J]. Oncol Res, 2001, 12: 429-440.
[17] FieldsMT, Eisbruch A, Normolle D, et al. Radiosensitization produced in vivo by once- vs. twice-weekly 2’2’-difluoro-2’-deoxycytidine (gemcitabine) [J]. Int J Radiat Oncol Biol Phys, 2000, 47: 785-791.
[18] Fortunato J E, Mauceri HJ, Kocharyan H, et al. Gene therapy enhances the antiproliferative effect of radiation in intimal hyperplasia [J]. J Surg Res, 2000, 89: 155-162.
[19] Hahn SM, Bernhard EJ, Regine W, et al. A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer [J]. Clin Cancer Res, 2002, 8: 1065-1072.
[20] Hui ZG, Li YX, Yang WZ, et al. Abrogation of radiation-induced G2 arrest and radiosensitization by 7-hydroxystauros-porine (UCN-01) in human nasopharyngeal carcinoma cell line [J]. Chin J Cancer, 2003, 22: 6-10.
[21] Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, et al. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier : tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics [J]. Int J Radiat Oncol Biol Phys, 2001, 49: 1133-1139.
[22] Lawrence TS, Nyati MK. Small-molecule tyrosine kinase inhibitors as radiosensitizers et al. Semin Radiat Oncol, 2002, 12: 33-36.
[23] Li QL, Peng ZL, Wang H, et al. Effects of cytosine deaminase gene transfer and the combined therapy with radiation in vitro on cervical cancer cells [J]. Pract J Cancer, 2002, 17: 259-262.
[24] Lu WP, Li SY, An P, et al. A study on the radiosensitizing effects of CD/5-FC on rectal cancer cells [J]. Chin J Gen Surg, 2002, 17: 440-441.
[25] Matsuoka H, Shibamoto Y, Kubota T, et al. In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas [J]. Oncol Rep, 2000, 7: 23-26.
[26] McKenna WG, Muschel RJ, Gupta AK, et al. Farnesyltransferase inhibitors as radiation sensitizers [J]. Semin Radiat Oncol, 2002, 12: 27-32.
[27] Park SH, Chung YM, Lee YS, et al. Antisense of human peroxiredoxin II enhances radiation-induced cell death [J]. Clin Cancer Res, 2000, 6: 4915-4920.
[28] Rao GS, Murray S, Ethier SP. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor [J]. Int J Radiat Oncol Biol Phys, 2000, 48: 1519-1528.
[29] Rao ZG, Zhang JR, Zheng YF, et al. Radiation sensitizing effect of anti HPV16E6-ribozyme on cervical carcinoma cell line [J]. Chin J Cancer, 2002, 21: 149-152.
[30] Rhomberg W, Jasarevic Z, Alton R, et al. Aggressive angiomyxoma : irradiation for recurrent disease [J]. Strahlenther Onkol, 2000, 176: 324-326.
[31] Rockwell S, Donnelly E-T, Liu YF, et al. Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro [J]. Int J Radiat Oncol Biol Phys, 2002, 54: 536-541.
[32] Rosenthal DI, Becerra CR, Toto RD, et al. Reversible renal toxicity resulting from high single doses of the new radiosensitizer gadolinium texaphyrin [J]. Am J Clin Oncol, 2000, 23: 593-598.
[33] Russo SM, Tepper J E, Baldwin ASJr, et al. Enhancement of radiosensitivity by proteasome inhibition : implications for a role of NF-kappaB [J]. Int J Radiat Oncol Biol Phys, 2001, 50: 183-193.
[34] Schaffer M, Schaffer PM, Corti L, et al. Photofrin II as an efficient radiosensitizing agent in an experimental tumor [J]. Onkologie, 2001, 24: 482-485.
[35] Schaffer M, Schaffer PM, Corti L, et al. Photofrin as a specific radiosensitizing agent for tumors : studies in comparison to other porphyrins, in an experimental in vivo model [J]. J Photochem Photobiol B : Biol, 2002, 66: 157-164.
[36] Si JL, Qi YQ, Tao XG, et al. Effects of telomerase inhibitor combined with radiotherapy on gastric cancer in mice [J]. Cancer Res Prev Treat, 2003, 30: 32-33.
[37] Tenzer A, Zingg D, Rocha S, et al. The phosphatidylinositide 3’-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C [J]. Cancer Res, 2001, 61: 8203-8210.
[38] Tian H, Wittmack EK, Jorgensen TJ. p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis [J]. Cancer Res, 2000, 60: 679-684.
[39] Wang XP, Yun S, Zhang XL, et al. Primary clinical study of radiosensitizer CMNa [J]. Chin Clin Oncol, 2003, 8: 28-32.
[40] Xiao SW, Zhang SW, Lu YY, et al. Enhancement of radio-sensitivity of human gastric carcinoma cell lines by adenovirus-mediated delivery of the p53 gene [J]. J Peking Univ (Health Sci), 2001, 33: 427-431.
[41] Yang SJ, Zhang XL, Jiang ML, et al. Unusual radiation response of gemcitabine-treated HeLa cells reduced and enhanced survival [J]. Cancer Letters, 2002, 187: 179-183.
[42] Zhang WH, Zhang R, Wu LY, et al. Gemcitabine in advanced and recurrent gynecological malignant tumor : A preliminary analysis [J]. J Oncol, 2002, 8: 193-195.
[43] Zheng XL, Meng XS, Zhao F, et al. The in situ tumor response to radiosensitization a novel sensitizer sodium glycididazole [J]. J Radiat Res Radiat Proces, 2000, 18: 91-95.
[44] Zou C, Guan Y, Zou C, et al. N-(4-hydroxyphenyl) retinamide (4-HPR) modulates GADD45 expression in radiosensitive bladder cancer cell lines [J]. Cancer Lett, 2002, 180: 131-137. |
>
>